Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements

Melinda S. Schaller, Greg J. Zahner, Warren J. Gasper, William Harris, Michael S. Conte, Nancy K. Hills, S. Marlene Grenon

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Oral supplementation with n-3 polyunsaturated fatty acids (PUFA) increases the omega-3 index, a biomarker of red blood cell eicosapentaenoic acid and docosahexaenoic acid, and plasma levels of biosynthesis pathway markers and potent lipid mediators involved in the resolution of inflammation among patients with peripheral arterial disease (PAD). Objective: We aimed to quantify the association between an upstream change in the omega-3 index and downstream changes in lipid mediator production. Methods: We conducted a secondary analysis of the OMEGA-PAD I Trial, a randomized, placebo controlled trial investigating high-dose n-3 PUFA oral supplementation in PAD patients. Eighty subjects were randomized to either 4.4 g of fish oil or placebo for 1 month. Regression analyses using generalized estimating equation techniques were used to investigate the relationship between changes in the omega-3 index and changes in lipid mediators, pre- and post-intervention. Results: In the fish oil group, there was a significant increase in the omega-3 index (5 ± 1% to 9 ± 2%, P < .001) as well as in the plasma levels of several downstream lipid mediator pathway markers of resolution, which are involved with the regulation of leukocyte effector function and host defense. A doubling of the omega-3 index correlated with increases of 2.3-fold in 18-hydroxy-eicosapentaenoic acid (HEPE; P < .0001), 1.7-fold in 15-HEPE (P = .03), 1.9-fold in 5-HEPE (P = .04), and 3.6-fold in 4-hydroxy-docosahexaenoic acid (P < .001). Conclusion: Among subjects with symptomatic PAD who took oral fish oil supplements for 1 month, observed changes in the omega-3 index were strongly associated with increases in downstream mediators in the biochemical pathways of resolution.

Original languageEnglish (US)
JournalJournal of Clinical Lipidology
DOIs
StateAccepted/In press - 2017
Externally publishedYes

Fingerprint

Fish Oils
Peripheral Arterial Disease
Lipids
Hydroxy Acids
Eicosapentaenoic Acid
Docosahexaenoic Acids
Omega-3 Fatty Acids
Placebos
Leukocytes
Randomized Controlled Trials
Erythrocytes
Biomarkers
Regression Analysis
Inflammation

Keywords

  • Fish oil
  • Lipid mediators
  • N-3 polyunsaturated fatty acids
  • Omega-3 index
  • Peripheral artery disease
  • Resolution of inflammation
  • Specialized pro-resolving mediators

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics
  • Cardiology and Cardiovascular Medicine

Cite this

Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements. / Schaller, Melinda S.; Zahner, Greg J.; Gasper, Warren J.; Harris, William; Conte, Michael S.; Hills, Nancy K.; Grenon, S. Marlene.

In: Journal of Clinical Lipidology, 2017.

Research output: Contribution to journalArticle

Schaller, Melinda S. ; Zahner, Greg J. ; Gasper, Warren J. ; Harris, William ; Conte, Michael S. ; Hills, Nancy K. ; Grenon, S. Marlene. / Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements. In: Journal of Clinical Lipidology. 2017.
@article{587e3f47e8264238b3d565d6a40df06c,
title = "Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements",
abstract = "Background: Oral supplementation with n-3 polyunsaturated fatty acids (PUFA) increases the omega-3 index, a biomarker of red blood cell eicosapentaenoic acid and docosahexaenoic acid, and plasma levels of biosynthesis pathway markers and potent lipid mediators involved in the resolution of inflammation among patients with peripheral arterial disease (PAD). Objective: We aimed to quantify the association between an upstream change in the omega-3 index and downstream changes in lipid mediator production. Methods: We conducted a secondary analysis of the OMEGA-PAD I Trial, a randomized, placebo controlled trial investigating high-dose n-3 PUFA oral supplementation in PAD patients. Eighty subjects were randomized to either 4.4 g of fish oil or placebo for 1 month. Regression analyses using generalized estimating equation techniques were used to investigate the relationship between changes in the omega-3 index and changes in lipid mediators, pre- and post-intervention. Results: In the fish oil group, there was a significant increase in the omega-3 index (5 ± 1{\%} to 9 ± 2{\%}, P < .001) as well as in the plasma levels of several downstream lipid mediator pathway markers of resolution, which are involved with the regulation of leukocyte effector function and host defense. A doubling of the omega-3 index correlated with increases of 2.3-fold in 18-hydroxy-eicosapentaenoic acid (HEPE; P < .0001), 1.7-fold in 15-HEPE (P = .03), 1.9-fold in 5-HEPE (P = .04), and 3.6-fold in 4-hydroxy-docosahexaenoic acid (P < .001). Conclusion: Among subjects with symptomatic PAD who took oral fish oil supplements for 1 month, observed changes in the omega-3 index were strongly associated with increases in downstream mediators in the biochemical pathways of resolution.",
keywords = "Fish oil, Lipid mediators, N-3 polyunsaturated fatty acids, Omega-3 index, Peripheral artery disease, Resolution of inflammation, Specialized pro-resolving mediators",
author = "Schaller, {Melinda S.} and Zahner, {Greg J.} and Gasper, {Warren J.} and William Harris and Conte, {Michael S.} and Hills, {Nancy K.} and Grenon, {S. Marlene}",
year = "2017",
doi = "10.1016/j.jacl.2017.06.011",
language = "English (US)",
journal = "Journal of Clinical Lipidology",
issn = "1933-2874",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements

AU - Schaller, Melinda S.

AU - Zahner, Greg J.

AU - Gasper, Warren J.

AU - Harris, William

AU - Conte, Michael S.

AU - Hills, Nancy K.

AU - Grenon, S. Marlene

PY - 2017

Y1 - 2017

N2 - Background: Oral supplementation with n-3 polyunsaturated fatty acids (PUFA) increases the omega-3 index, a biomarker of red blood cell eicosapentaenoic acid and docosahexaenoic acid, and plasma levels of biosynthesis pathway markers and potent lipid mediators involved in the resolution of inflammation among patients with peripheral arterial disease (PAD). Objective: We aimed to quantify the association between an upstream change in the omega-3 index and downstream changes in lipid mediator production. Methods: We conducted a secondary analysis of the OMEGA-PAD I Trial, a randomized, placebo controlled trial investigating high-dose n-3 PUFA oral supplementation in PAD patients. Eighty subjects were randomized to either 4.4 g of fish oil or placebo for 1 month. Regression analyses using generalized estimating equation techniques were used to investigate the relationship between changes in the omega-3 index and changes in lipid mediators, pre- and post-intervention. Results: In the fish oil group, there was a significant increase in the omega-3 index (5 ± 1% to 9 ± 2%, P < .001) as well as in the plasma levels of several downstream lipid mediator pathway markers of resolution, which are involved with the regulation of leukocyte effector function and host defense. A doubling of the omega-3 index correlated with increases of 2.3-fold in 18-hydroxy-eicosapentaenoic acid (HEPE; P < .0001), 1.7-fold in 15-HEPE (P = .03), 1.9-fold in 5-HEPE (P = .04), and 3.6-fold in 4-hydroxy-docosahexaenoic acid (P < .001). Conclusion: Among subjects with symptomatic PAD who took oral fish oil supplements for 1 month, observed changes in the omega-3 index were strongly associated with increases in downstream mediators in the biochemical pathways of resolution.

AB - Background: Oral supplementation with n-3 polyunsaturated fatty acids (PUFA) increases the omega-3 index, a biomarker of red blood cell eicosapentaenoic acid and docosahexaenoic acid, and plasma levels of biosynthesis pathway markers and potent lipid mediators involved in the resolution of inflammation among patients with peripheral arterial disease (PAD). Objective: We aimed to quantify the association between an upstream change in the omega-3 index and downstream changes in lipid mediator production. Methods: We conducted a secondary analysis of the OMEGA-PAD I Trial, a randomized, placebo controlled trial investigating high-dose n-3 PUFA oral supplementation in PAD patients. Eighty subjects were randomized to either 4.4 g of fish oil or placebo for 1 month. Regression analyses using generalized estimating equation techniques were used to investigate the relationship between changes in the omega-3 index and changes in lipid mediators, pre- and post-intervention. Results: In the fish oil group, there was a significant increase in the omega-3 index (5 ± 1% to 9 ± 2%, P < .001) as well as in the plasma levels of several downstream lipid mediator pathway markers of resolution, which are involved with the regulation of leukocyte effector function and host defense. A doubling of the omega-3 index correlated with increases of 2.3-fold in 18-hydroxy-eicosapentaenoic acid (HEPE; P < .0001), 1.7-fold in 15-HEPE (P = .03), 1.9-fold in 5-HEPE (P = .04), and 3.6-fold in 4-hydroxy-docosahexaenoic acid (P < .001). Conclusion: Among subjects with symptomatic PAD who took oral fish oil supplements for 1 month, observed changes in the omega-3 index were strongly associated with increases in downstream mediators in the biochemical pathways of resolution.

KW - Fish oil

KW - Lipid mediators

KW - N-3 polyunsaturated fatty acids

KW - Omega-3 index

KW - Peripheral artery disease

KW - Resolution of inflammation

KW - Specialized pro-resolving mediators

UR - http://www.scopus.com/inward/record.url?scp=85026535102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026535102&partnerID=8YFLogxK

U2 - 10.1016/j.jacl.2017.06.011

DO - 10.1016/j.jacl.2017.06.011

M3 - Article

JO - Journal of Clinical Lipidology

JF - Journal of Clinical Lipidology

SN - 1933-2874

ER -